Abstract
Acute mastoiditis is a potential complication of acute otitis media (AOM), with Streptococcus pneumoniae historically the most common pathogen isolated. Following the release of the 7-valent pneumococcal conjugate vaccine in 2000, a marked decline in invasive pneumococcal disease and a smaller reduction in pneumococcal AOM were observed, but data regarding its impact on acute mastoiditis are limited. With the recent introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), it is anticipated that pneumococcal AOM and invasive disease will further diminish. We report a case of acute mastoiditis from a multidrug-resistant serotype 19A S. pneumoniae in an immunocompetent child who had received three PCV13 vaccinations.
Published by Elsevier Ireland Ltd.
MeSH terms
-
Acute Disease
-
Anti-Bacterial Agents / therapeutic use
-
Combined Modality Therapy
-
Drug Resistance, Multiple, Bacterial*
-
Female
-
Fever / diagnosis
-
Fever / etiology
-
Follow-Up Studies
-
Humans
-
Infant
-
Mastoiditis / microbiology*
-
Mastoiditis / physiopathology
-
Mastoiditis / therapy*
-
Microbial Sensitivity Tests
-
Middle Ear Ventilation / methods
-
Pneumococcal Infections / diagnosis
-
Pneumococcal Infections / prevention & control*
-
Pneumococcal Vaccines / administration & dosage*
-
Risk Assessment
-
Serotyping
-
Severity of Illness Index
-
Streptococcus pneumoniae / classification
-
Streptococcus pneumoniae / drug effects*
-
Time Factors
-
Treatment Outcome
-
Vaccines, Conjugate / administration & dosage
Substances
-
13-valent pneumococcal vaccine
-
Anti-Bacterial Agents
-
Pneumococcal Vaccines
-
Vaccines, Conjugate